4G7SDIE |
|
Clinical |
Synimmune, The University Of Tubingen |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) |
|
Phase 1 Clinical |
University Hospitals Cleveland Medical Center |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD22/CD19 monoclonal antibody-toxin conjugate |
|
Phase 1 Clinical |
Ut Southwestern Medical Center |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
aCD19z |
aCD19z |
Phase 1 Clinical |
Christie Hospital Nhs Foundation Trust |
Lymphoma, Non-Hodgkin |
Details
|
PTG-01 |
PTG-01 |
Phase 1 Clinical |
Protheragen |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
H-31970-SAGAN |
H-31970-SAGAN |
Phase 1 Clinical |
Baylor College Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD20 CAR-T Cell Therapy (PersonGen) |
|
Phase 1 Clinical |
|
|
Details
|
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) |
|
Clinical |
Leidos |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19-CAR |
CD19-CAR |
Phase 1 Clinical |
The University Of Texas MD Anderson Cancer Center |
Leukemia; Lymphoma |
Details
|
Virus-specific-CD19.CAR |
|
Phase 1 Clinical |
Baylor College Of Medicine |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) |
|
Phase 2 Clinical |
Southwest Hospital Chongqing |
Lymphoma, Large B-Cell, Diffuse |
Details
|
CD19.CAR-VST |
CD19.CAR-VST |
Phase 1 Clinical |
Baylor College Of Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) |
|
Phase 2 Clinical |
Wuhan Bio-Raid Biotechnology |
Hematologic Diseases; Lymphoma, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) |
|
Phase 1 Clinical |
Nagoya University, Shinshu University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) |
PZ-01 |
Clinical |
Pinze Lifetechnology |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CLIC-1901 (Ottawa Hospital Research Institute) |
CLIC-1901 |
Phase 2 Clinical |
Ottawa Hospital Research Institute |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology |
Leukemia, Lymphoid |
Details
|
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) |
|
Phase 1 Clinical |
Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) |
yinnuokati-19 |
Phase 2 Clinical |
Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) |
XLCART-001 |
Phase 2 Clinical |
Nanjing Medical University |
Lymphoma, B-Cell |
Details
|
3rd-gen-CD19-CAR |
3rd-gen-CD19-CAR |
Phase 2 Clinical |
Bluebird Bio |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) |
BPX-401 |
Phase 2 Clinical |
Bellicum Pharmaceuticals, Ospedale Pediatrico Bambino Gesu |
Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma |
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) |
WZTL002-1 |
Phase 1 Clinical |
The Malaghan Institute Of Medical Research |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Lymphoma, B-Cell |
Details
|
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) |
CARCIK-CD19; CIK-CAR.CD19 |
Phase 2 Clinical |
Fondazione Matilde Tettamanti Menotti De Marchi Onlus |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) |
|
Phase 1 Clinical |
Henan Provincial Cancer Hospital |
Lymphoma, B-Cell |
Details
|
U-CART (Shanghai Bioray Laboratory Inc) |
|
Phase 2 Clinical |
|
Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 2 Clinical |
The First Affiliated Hospital Of Nanchang University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (Sinobioway) |
|
Phase 2 Clinical |
Sinobioway Biomedicine Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma |
Details
|
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) |
|
Phase 1 Clinical |
Beijing Yongtai Rec Biotechnology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19 CAR-T cell therapy (National University of Malaysia) |
|
Phase 3 Clinical |
National University Of Malaysia |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CART-19 cells (Henan Hualong Biotechnology) |
|
Phase 2 Clinical |
Henan Hualong Biotechnology |
Leukemia, Lymphoid |
Details
|
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) |
|
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital |
Leukemia |
Details
|
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) |
|
Phase 1 Clinical |
Shanghai Jiaotong University |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) |
|
Phase 1 Clinical |
Kunming Medical University |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy |
GC-197 |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19 CAR-T (HuaDao CAR-Tcell) |
|
Phase 1 Clinical |
Huadao (Shanghai) Biopharma Co Ltd |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell |
Details
|
K-193 |
K-193 |
Phase 1 Clinical |
Beijing Lvzhu Biological Technology Co Ltd |
Lymphoma, B-Cell |
Details
|
CN-201 |
CN-201 |
Phase 1 Clinical |
Tongrun Biomedicine (Shanghai) Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
CLBR-001/SWI-019 |
CLBR-001/SWI-019 |
Phase 1 Clinical |
Abbvie Inc, California Institute For Biomedical Research |
Lymphoma, B-Cell |
Details
|
KUR-502 CD19 CAR-NKT |
KUR-502; CMD-502 |
Phase 1 Clinical |
Athenex Inc |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) |
|
Phase 1 Clinical |
Uclas Jonsson Comprehensive Cancer Center |
Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Autologous CAR19 T lymphocytes Therapy |
|
Phase 1 Clinical |
Institute of Hematology and Blood Transfusion, Czech Republic |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) |
|
Phase 1 Clinical |
The General Hospital Of The People'S Liberation Army |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
NCAR19-T |
|
Phase 2 Clinical |
Second Military Medical University Of Chinese People'S Liberation Army |
Lymphoma, B-Cell |
Details
|
UCART019 |
UCART-019 |
Phase 2 Clinical |
The General Hospital Of The People'S Liberation Army |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
TanCART19/20 |
|
Phase 1 Clinical |
The General Hospital Of The People'S Liberation Army |
Neuromyelitis Optica |
Details
|
19273-4SCAR |
19273-4SCAR |
Phase 2 Clinical |
Peking University |
Lymphoma, B-Cell |
Details
|
4-1BBz CD19-Her2tG (Seattle Children's Hospital) |
|
Phase 1 Clinical |
Seattle Children'S Hospital |
Neoplasms |
Details
|
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) |
|
Phase 2 Clinical |
Pla General Hospital |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) |
|
Phase 1 Clinical |
Second Affiliated Hospital Of Zhejiang University School Of Medicine |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma |
Details
|
MCM-998 |
MCM-998; LXG-250 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
CC-312 |
CC-312 |
Phase 1 Clinical |
|
|
Details
|
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Leukemia; Lymphoma |
Details
|
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) |
|
Phase 1 Clinical |
Aikangd Biomedical Technology (Suzhou) Co Ltd |
Leukemia; Lymphoma |
Details
|
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) |
ICTCAR-014 |
Phase 2 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) |
CAR-20/19-T cells |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) |
|
Phase 1 Clinical |
Stanford University |
Lymphoma, B-Cell |
Details
|
Ensomafusp alfa |
RG-6076 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
|
Details
|
Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) |
|
Phase 1 Clinical |
City Of Hope National Medical Center |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin |
Details
|
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
|
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell |
Details
|
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) |
bi-4SCAR CD19/79b |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell |
Details
|
JCAR-014 |
JCAR-014 |
Phase 2 Clinical |
Fred Hutchinson Cancer Research Center, Juno Therapeutics, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) |
|
|
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
|
Details
|
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) |
|
|
Fred Hutchinson Cancer Research Center |
|
Details
|
CTA-101 |
CTA-101 |
Phase 1 Clinical |
Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) |
|
Phase 2 Clinical |
Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Obexelimab |
XmAb-5871; AMG-729 |
|
Xencor |
|
Details
|
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) |
|
|
Hebei Senlang Biological Technology Co Ltd |
|
Details
|
SGN-CD19B |
SGN-CD19B |
|
Seattle Genetics Inc |
|
Details
|
Acmucabtagene autoleucel |
TAC01-CD19; TAC-921; CD19-TAC01 |
|
Triumvira Immunologics |
|
Details
|
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells |
TAK-940 |
|
Takeda |
Neoplasms |
Details
|
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) |
|
Phase 1 Clinical |
First Affiliated Hospital Of Zhejiang University |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Murine CD19 CAR-T cell therapy (Yake) |
|
|
Shanghai YaKe Biotechnology Co Ltd |
|
Details
|
PBLTT52CAR19 |
|
Phase 1 Clinical |
Great Ormond Street Hospital For Children Nhs Foundation Trust |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
GC019F |
|
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
Anti-human CD19-CD22 T cell therapy |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
FT-819 |
FT-8198; FT-819 |
Phase 1 Clinical |
Fate Therapeutics |
Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University |
Multiple Myeloma |
Details
|
CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) |
|
Phase 2 Clinical |
Nanfang Hospital Of Southern Medical University |
Leukemia, Biphenotypic, Acute |
Details
|
CTA-30X |
CTA30X; CTA-30X |
Phase 1 Clinical |
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) |
HX-s001; YTS101; HX-s001/YTS101; HXYT-001 |
Phase 1 Clinical |
Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
C-CAR039 |
EXP-039; C-CAR039; C-CAR-039 |
Phase 1 Clinical |
Cellular Biomedicine Group Ltd |
Lymphoma, Non-Hodgkin |
Details
|
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) |
|
Phase 1 Clinical |
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) |
|
Phase 1 Clinical |
Wuhan Union Hospital |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anbalcabtagene autoleucel |
CRC-01 |
|
Curocell Inc |
|
Details
|
RPM CD19-mbIL15-CAR-T cell therapy (Eden BioCell) |
|
|
|
|
Details
|
RGV-004 |
RGV-004 |
Phase 1 Clinical |
Hangzhou Rongu Biotechnology Co Ltd |
Lymphoma, B-Cell |
Details
|
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) |
CT-120 |
Phase 2 Clinical |
Nanjing Iaso Biotherapeutics Co Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
ThisCART-19 |
ThisCART-19 |
|
Fundamenta Therapeutics Ltd |
|
Details
|
FT-596 |
FT-596 |
Phase 1 Clinical |
Fate Therapeutics Inc |
Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Obecabtagene autoleucel |
AUTO1; Obe-cel; AUTO-1 |
|
University College London |
|
Details
|
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) |
|
Phase 1 Clinical |
University Of Colorado, Denver, Usa |
Lymphoma, Non-Hodgkin |
Details
|
GC-502 |
GC-502 |
|
Gracell Biotechnologies (Shanghai) Co Ltd |
|
Details
|
ALLO-501A |
ALLO-501A |
|
Allogene Therapeutics Inc |
|
Details
|
Allogeneic CD-19 CAR-T Cell Therapy |
|
|
Shenzhen University General Hospital |
|
Details
|
Bispecific CD19/22 CAR T cells |
|
|
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
|
Details
|
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) |
|
|
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
|
Details
|
IMJ-995 |
IMJ-995 |
|
Novartis Pharma Ag |
|
Details
|
SNUH-CD19-CAR-T Cell Therapy |
SNUH-CD19-CAR-T |
|
Seoul National University Hospital |
|
Details
|
CD19-UCART |
CD-19-UCART; CD19-UCART |
Phase 1 Clinical |
Bioray Laboraytories Inc |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) |
|
|
China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital |
|
Details
|
BinD-19 (Shenzhen BinDeBio) |
BinD-19 |
|
Shenzhen Bindebio Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Azercabtagene zapreleucel |
PBCAR-0191 |
Phase 2 Clinical |
Baxalta |
Hematologic Neoplasms; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin |
Details
|
C-CAR011 |
|
|
Pla General Hospital |
Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
ALLO-501 |
ALLO-501 |
|
Cellectis |
|
Details
|
KITE-363 |
KITE-363 |
Phase 1 Clinical |
Kite Pharma |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse |
Details
|
CD19-CART (Unicar-Therapy Bio-medicine Technology) |
|
|
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
|
Details
|
YTB-323 |
YTB-323 |
Phase 2 Clinical |
Novartis Pharma Ag |
Lymphoma, Large B-Cell, Diffuse |
Details
|
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory) |
|
|
Bioray Laboraytories Inc |
|
Details
|
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) |
ssCART-19 |
Phase 1 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
HuCART19 |
|
|
National Cancer Institute, Kite Pharma |
|
Details
|
Coltuximab ravtansine |
SAR-3419; huB4-DM4 |
|
Immunogen |
|
Details
|
TC-110 |
TC-110 |
|
Tcr2 Therapeutics |
|
Details
|
CC-97540 |
CC-97540 |
|
Juno Therapeutics |
|
Details
|
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
|
The First Affiliated Hospital Of Nanchang University |
|
Details
|
GC-012F |
GC-012F |
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) |
|
|
University Of Alberta |
|
Details
|
Anti-CD19 CAR T-cell therapy (University College London) |
4G7-CARD |
|
University College London |
|
Details
|
Humanized CD19 CAR-T cell therapy (Yake) |
YK-C19 |
Phase 1 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Leukemia, Lymphoid |
Details
|
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) |
|
|
Shanghai Genechem Co Ltd |
|
Details
|
CD19.CAR T Cells (University Hospital Heidelberg) |
|
|
University Of Heidelberg |
|
Details
|
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) |
|
|
Xuanwu Hospital Of Capital Medical University |
|
Details
|
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) |
|
|
Xinqiao Hospital, Army Medical University |
|
Details
|
XYF19 CAR-T Cell Therapy |
XYF-19 |
|
Xi'An Yufan Biotechnology Co Ltd |
|
Details
|
CAR-CD19 T cell therapy |
|
Phase 2 Clinical |
Carsgen Biomedicine (Shanghai) Co Ltd |
Lymphoma, Non-Hodgkin |
Details
|
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) |
|
|
Fujian Medical University |
|
Details
|
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) |
4SCAR-19 |
|
Shenzhen Geno-Immune Medical Institute |
|
Details
|
AMG-562 |
AMG-562 |
|
Amgen Inc |
|
Details
|
TG-1801 |
NI-1701; TG-1801 |
|
Novimmune |
|
Details
|
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) |
|
Phase 1 Clinical |
Chengdu Yinhe Biomedicine Co Ltd, Beijing Mali Biotechnology Co Ltd |
Lymphoma, B-Cell |
Details
|
pCAR-19B |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) |
|
|
Hrain Biotechnology |
|
Details
|
AFM-11 |
AFM-11 |
|
Affimed |
|
Details
|
CD19 CAR-T cell therapy (Chongqing Precision Biotech) |
|
|
Chongqing Precision Biotechnology Co Ltd |
|
Details
|
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) |
|
|
Shanghai Zhongshan Hospital, Hrain Biotechnology |
|
Details
|
Evoncabtagene pazurgedleucel |
CTX-110 |
|
Crispr Therapeutics |
|
Details
|
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) |
|
|
Chaim Sheba Medical Center At Tel Hashomer |
|
Details
|
GC007g |
GC-007G |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell |
Details
|
MDX 1342 |
MDX-1342 |
|
Medarex |
|
Details
|
CAR-T 19 cell therapy (University of Pennsylvania) |
|
|
University Of Pennsylvania |
|
Details
|
A-319 |
A-319 |
Phase 1 Clinical |
Evive Biotech Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) |
|
|
The University Of Texas MD Anderson Cancer Center |
|
Details
|
IKS-03 |
IKS-03 |
Phase 1 Clinical |
Iksuda Therapeutics |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell |
Details
|
CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) |
|
Phase 1 Clinical |
Sabz Biomedicals |
Leukemia, Biphenotypic, Acute |
Details
|
Anti-BCMA/CD19 CAR-T Therapy(University College London) |
|
Phase 1 Clinical |
University College London |
Multiple Myeloma |
Details
|
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) |
|
Phase 2 Clinical |
Kk Women'S And Children'S Hospital |
Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) |
PL-001 |
Phase 2 Clinical |
Pell Bio-Med Technology Co Ltd |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma |
Details
|
GB5005 chimeric antigen receptor T cell therapy (Genbase) |
|
Phase 1 Clinical |
Shanghai Genbase Biotechnology Co Ltd |
Leukemia, B-Cell |
Details
|
CAR-20-19-22 |
CAR-20-19-22 |
Phase 1 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) |
|
Phase 3 Clinical |
Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Juventas) |
CNCT19; CNCT-19; HY001 |
Phase 2 Clinical |
|
Lymphoma, B-Cell; Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19 CARvac T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) |
|
Phase 1 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
TNB-486 |
TNB-486 |
Phase 1 Clinical |
Teneobio Inc |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin |
Details
|
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) |
|
Phase 1 Clinical |
University Of Colorado |
Lymphoma, B-Cell; Lymphoma, Non-Hodgkin |
Details
|
ICT19G1 |
ICT-19G1 |
Phase 1 Clinical |
Innovative Cellular Therapeutics Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CTL-119 |
CTL-119 |
Phase 1 Clinical |
Novartis Pharma Ag, University Of Pennsylvania |
Multiple Myeloma |
Details
|
TI-1007 |
TI-1007 |
Phase 1 Clinical |
Tianjin Timmune Biotech Inc |
Lymphoma, B-Cell |
Details
|
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) |
4SCAR19/22 |
Phase 2 Clinical |
Shenzhen Geno-Immune Medical Institute |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
CD19-CAR-DNT cells Therapy(Zhejiang Ruijiamei Biotechnologies Co Ltd) |
|
Phase 1 Clinical |
|
Lymphoma, B-Cell |
Details
|
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) |
SENL-B19 |
Phase 2 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Lymphoma, B-Cell; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma |
Details
|
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) |
|
Phase 1 Clinical |
Immune Cell |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
Anti-CD19 CAR-T cell therapy (Uppsala University) |
|
Phase 2 Clinical |
Uppsala University |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
ET190L1-ARTEMIS T cells (Eureka Therapeutics) |
ET190L1-ARTEMI; ET-190; ET190L1; ET190 |
Phase 1 Clinical |
Eureka Therapeutics |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
MB-CART19.1 (Miltenyi Biotec) |
|
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
GC-007F (Gracell Biotechnology) |
GC-007F |
Phase 1 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19 chimeric antigen receptor T cell therapy (Takara Bio) |
TBI-1501 |
Phase 2 Clinical |
Memorial Sloan Kettering Cancer Center, Takara Bio Inc |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Senl-1904A |
Senl-1904A; Senl_1904A |
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Zamtocabtagene autoleucel |
MB-CART2019.1 |
Phase 2 Clinical |
Miltenyi Biotec |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin |
Details
|
MC-19PD1 CAR-T cell therapy (Peking University) |
|
Phase 1 Clinical |
Peking University |
Lymphoma |
Details
|
ET-019002 |
ET-019002 |
Phase 1 Clinical |
Eureka Therapeutics |
Lymphoma, B-Cell; Neoplasms |
Details
|
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 2 Clinical |
Suzhou University |
Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) |
|
Phase 2 Clinical |
National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh |
Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation |
Details
|
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) |
|
Phase 1 Clinical |
Juno Therapeutics |
Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
GC-022 |
GC-022; GC-022F |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) |
|
Phase 1 Clinical |
Tianjin Timmune Biotech Inc |
Leukemia |
Details
|
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) |
|
Phase 1 Clinical |
Shanghai Longyao Biological Technology Co Ltd |
Leukemia, Myeloid, Acute |
Details
|
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) |
|
Phase 1 Clinical |
Kecellitics Biotech Company Ltd |
Lymphoma |
Details
|
TAK-007 |
TAK-007 |
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Lymphoma, Non-Hodgkin |
Details
|
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) |
|
Phase 1 Clinical |
Tianjin Mycure Medical Technology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR T-cell therapy (Fujian Medical University) |
|
Phase 3 Clinical |
Fujian Medical University |
Lymphoma, B-Cell |
Details
|
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Lymphoma, B-Cell; Leukemia, B-Cell |
Details
|
GNR-084 |
GNR-084 |
Phase 2 Clinical |
Generium Pharmaceuticals, Iontas |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) |
|
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) |
|
Phase 1 Clinical |
The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
CD19-STAR-T cell therapy (China Immunotech Co Ltd) |
|
Phase 1 Clinical |
Hebei Yanda Hospital, China Immunotech Co Ltd |
Lymphoma, B-Cell |
Details
|
CD19-CART |
|
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) |
|
Phase 1 Clinical |
Second Affiliated Hospital School Of Zhejiang University School Of Medicine |
Lymphoma, Non-Hodgkin |
Details
|
BZ019 |
BZ-019 |
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
CD19/CD22 dual-target CAR-T (Yake biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
Anti-CD19 CAR-Engineered NK Cells therapy (Simnova) |
CAR-NK-CD19 |
Phase 1 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell |
Details
|
UCART-19 |
S-68587; UCART-19 |
Phase 1 Clinical |
Cellectis |
Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
RO-7227166 |
RO-7227166 |
Phase 1 Clinical |
F. Hoffmann-La Roche Ltd |
Lymphoma, Non-Hodgkin |
Details
|
Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
Details
|
IM19CAR-T |
|
Phase 2 Clinical |
Beijing Yimiao Medical Technology Co Ltd |
Hematologic Neoplasms; Leukemia; Neoplasms; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma |
Details
|
1-A-46 |
1-A-46; CMG1A46; CMG1A-46; BR110; 1A46 |
Phase 2 Clinical |
Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd |
Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
Emfizatamab |
GNC-038 |
Phase 2 Clinical |
Sichuan Baili Pharmaceutical Co Ltd |
Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) |
|
Phase 1 Clinical |
Shanghai Cellular Biopharmaceutical Group Ltd |
Lymphoma, B-Cell |
Details
|
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) |
|
Clinical |
Nanjing Kati Medical Technology Co Ltd |
Neoplasms |
Details
|